Travere Therapeutics, Inc. (TVTX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Travere Therapeutics, Inc. (TVTX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 37/100 — a percentile rank of Travere Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $5.4B |
| P / S | 9.1× |
| EV / EBITDA | 255.0× |
| Gross margin | 98.6% |
| Operating margin | -6.8% |
| Net margin | -7.4% |
| Return on equity | -177.2% |
| ROIC | -8.0% |
| Revenue growth | 77.1% |
| Debt / equity | 24.6× |
| Dividend yield | 0.0% |
Is Travere Therapeutics, Inc. overvalued? P/S looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Travere Therapeutics, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact